Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestors.amgen.com
Amgen News Release
Get the latest updates from Amgen News Release directly as they happen.
Follow now 111 followers
Latest posts
Last updated almost 5 years ago
Amgen and UCB Provide Regulatory Update on Status of EVENITY™ (romosozumab) in the EU
almost 5 years ago
THOUSAND OAKS, Calif. and BRUSSELS, June 27, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN)...
Amgen And MBC BioLabs Announce Winners Of The Amgen Golden Ticket
almost 5 years ago
Two Biotherapeutic Companies Receive Lab Space and Other Benefits to Further Advance...
Amgen And The Institute For Protein Design (IPD) At University Of Washington Announce Unique Strategic Research Partnership
almost 5 years ago
Collaboration Will Apply IPD's de novo Protein Design Expertise to Biotech Drug...
Amgen Announces BLINCYTO® (blinatumomab) Five-Year Overall Survival Data At EHA 2019
almost 5 years ago
Phase 2 Single-Arm BLAST Study Shows Median Overall Survival of 36.5 Months...
FDA Approves Amgen And Allergan's KANJINTI™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)
almost 5 years ago
Approval Based on Totality of Evidence Demonstrating KANJINTI is Biosimilar to Herceptin...
Amgen Publishes Offer Document With Respect To The Recommended Public Cash Offer To The Shareholders Of Nuevolution
almost 5 years ago
THOUSAND OAKS, Calif., June 12, 2019 /PRNewswire/ -- The Offer is not...
Intermountain Healthcare and deCODE genetics Launch Groundbreaking DNA Study of 500,000 People to Find New Links Between Genetics and Disease
almost 5 years ago
Study Represents Largest DNA Mapping Effort Undertaken in U.S. from a Single...
Amgen To Present At The Goldman Sachs 40th Annual Global Healthcare Conference
almost 5 years ago
THOUSAND OAKS, Calif., June 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present...
Amgen Announces First Clinical Data Evaluating Novel Investigational KRASG12C Inhibitor AMG 510 At ASCO 2019
almost 5 years ago
AMG 510 is the First KRASG12C Inhibitor to Reach Clinical Stage After...
Amgen Highlights The Versatility Of The BiTE® Immuno-Oncology Platform In Multiple Tumor Types At ASCO 2019
almost 5 years ago
Updated Phase 1 Data of Investigational AMG 420 in Relapsed and/or Refractory...
Amgen To Webcast Investor Meeting At 55th Annual Meeting Of The American Society Of Clinical Oncology (ASCO)
almost 5 years ago
THOUSAND OAKS, Calif., May 29, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will...
Additional Irrevocable Undertakings To Accept Amgen's Recommended Public Cash Offer To The Shareholders Of Nuevolution
almost 5 years ago
THOUSAND OAKS, Calif., May 28, 2019 /PRNewswire/ -- The Offer is not...